

Supporting information

Synthesis and structure-activity relationship studies of water-soluble β -cyclodextrin-glycyrrhetic acid conjugates as potential anti-influenza virus agents

Shuobin Liang^{a,1}, Man Li^{a,1}, Hongwei Jin^a, Yongmin Zhang^c, Lihe Zhang^a, Demin Zhou^a, Sulong Xiao^{a,b*}

^aState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

^bState Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China

^cSorbonne Université Institut Parisien de Chimie Moléculaire, CNRS UMR 8232, 4 place Jussieu, 75005 Paris, France

1. Synthesis of compounds **7**, **8**, **14-17** and **36** P4
2. Selected ¹H, ¹³C NMR and HRMS spectra P9

NMR or HRMS	Page
¹ H NMR of compound 9	S9
¹³ C NMR of compound 9	S9
HRMS of compound 9	S10
¹ H NMR of compound 10	S10
¹³ C NMR of compound 10	S11
HRMS of compound 10	S11
¹ H NMR of compound 11	S12
¹³ C NMR of compound 11	S12
HRMS of compound 11	S13
¹ H NMR of compound 12	S13
¹³ C NMR of compound 12	S14
HRMS of compound 12	S14

¹ H NMR of compound 18	S15
¹³ C NMR of compound 18	S15
HSQC of compound 18	S16
H-H COSY of compound 18	S16
HRMS of compound 18	S17
¹ H NMR of compound 19	S17
¹³ C NMR of compound 19	S18
HSQC of compound 19	S18
HRMS of compound 19	S19
¹ H NMR of compound 20	S19
¹³ C NMR of compound 20	S20
HSQC of compound 20	S20
HRMS of compound 20	S21

¹ H NMR of compound 21	S21
¹³ C NMR of compound 21	S22
HSQC of compound 21	S22
HRMS of compound 21	S23
¹ H NMR of compound 22	S23
¹³ C NMR of compound 22	S24
HSQC of compound 22	S24
HRMS of compound 22	S25
¹ H NMR of compound 23	S25
¹³ C NMR of compound 23	S26
HSQC of compound 23	S26
HRMS of compound 23	S27
¹ H NMR of compound 24	S27
¹³ C NMR of compound 24	S28
HSQC of compound 24	S28
HRMS of compound 24	S29
¹ H NMR of compound 25	S29
¹³ C NMR of compound 25	S30
HSQC of compound 25	S30
HRMS of compound 25	S31
¹ H NMR of compound 26	S31
¹³ C NMR of compound 26	S32
HSQC of compound 26	S32
HRMS of compound 26	S33
¹ H NMR of compound 27	S33
¹³ C NMR of compound 27	S34
HSQC of compound 27	S34
HRMS of compound 27	S35
¹ H NMR of compound 28	S35

¹³ C NMR of compound 28	S36
HRMS of compound 28	S36
¹ H NMR of compound 29	S37
¹³ C NMR of compound 29	S37
HRMS of compound 29	S38
¹ H NMR of compound 30	S38
¹³ C NMR of compound 30	S39
HSQC of compound 30	S39
HRMS of compound 30	S40
¹ H NMR of compound 31	S40
¹³ C NMR of compound 31	S41
HSQC of compound 31	S41
HRMS of compound 31	S42
¹ H NMR of compound 32	S42
¹³ C NMR of compound 32	S43
HRMS of compound 32	S43
¹ H NMR of compound 33	S44
¹³ C NMR of compound 33	S44
HSQC of compound 33	S45
HRMS of compound 33	S45
¹ H NMR of compound 34	S46
¹³ C NMR of compound 34	S46
HSQC of compound 34	S47
HRMS of compound 34	S47
¹ H NMR of compound 35	S48
¹³ C NMR of compound 35	S48
HSQC of compound 35	S49
HRMS of compound 35	S49
¹ H NMR of compound 37	S50

¹³ C NMR of compound 37	S50
HRMS of compound 37	S51
¹ H NMR of compound 38	S51
¹³ C NMR of compound 38	S52
HSQC of compound 38	S52
HRMS of compound 38	S53
¹ H NMR of compound 39	S53

¹³ C NMR of compound 39	S54
HSQC of compound 39	S54
HRMS of compound 39	S55
¹ H NMR of compound 40	S55
¹³ C NMR of compound 40	S56
HSQC of compound 40	S56
HRMS of compound 40	S57

1. Synthesis of compounds **7**, **8**, **14-17** and **36**

1.1 1H-benzotriazol-1-yl 3 β -hydroxy-11-oxo-olean-12-en-30-oate (**7**)^[1]

To a solution of glycyrrhetic acid **1** (4 g, 8.51 mmol) and TBTU (4 g, 12.4 mmol) in dry tetrahydrofuran (80 mL), DIPEA (2 mL, 1.21 mmol) was added. After continuous stirring at room temperature for 24 h, the solvent was removed by steaming. The residue was purified by column chromatography to give 4.5 g (90%) of compound **7** as a canary yellow solid. $R_f = 0.13$ (petroleum ether:ethyl acetate = 1:1); ¹H NMR (400 MHz, CDCl₃): δ 8.06 (d, 1H, $J = 8.4$ Hz), 7.55 (t, 1H, $J = 7.2$ Hz), 7.42 (t, 1H, $J = 7.4$ Hz), 7.33 (d, 1H, $J = 8.3$ Hz), 5.68 (s, 1H), 3.21 (dd, 1H, $J = 10.8, 5.4$ Hz), 2.74 (td, 1H, $J = 13.5, 3.4$ Hz), 2.32 (s, 1H), 2.14–0.94 (m, other aliphatic ring protons), 1.56, 1.41, 1.13, 1.11, 0.99, 0.91, 0.78 (s, each 3H, 7 \times CH₃), 0.68 (d, 1H, $J = 11.6$ Hz); ¹³C NMR (100 MHz, CDCl₃): δ 199.94, 172.53, 167.70, 143.49, 128.93, 128.84, 128.52, 124.83, 120.55, 78.64, 61.80, 55.26, 48.20, 45.34, 44.33, 43.13, 40.83, 39.07, 39.04, 37.70, 37.03, 32.68, 31.94, 31.11, 28.49, 28.03, 27.96, 27.16, 26.29, 23.42, 18.50, 17.07, 16.28, 15.52

1.2 (N-prop-2-yn-1-yl) (3 β ,20 β)-3-hydroxy-11-oxo-olean-12-en-29-amide (**8**)^[2]

To a solution of compound **7** (505 mg, 0.85 mmol) and 69 μ L propargyl amine (1.27 mmol) in DMF (15 mL) was added Na₂CO₃ (361 mg, 1.62 mmol). The resulting solution was stirred vigorously for 24 h at room temperature. The solvent was removed by steaming. The residue was purified by column chromatography to give 223 mg (51%) of compound **8** as a white solid. $R_f = 0.33$ (petroleum ether:ethyl acetate = 1:1); ¹H NMR (400 MHz, CDCl₃): δ 5.83 (t, 1H, $J = 4.2$ Hz), 5.68 (s, 1H), 4.11 (dd, 1H, $J = 17.4, 2.9$ Hz), 4.02 (dd, 1H, $J = 17.3, 2.9$ Hz), 3.22 (dd, 1H, $J = 10.2, 5.8$ Hz), 2.78 (td, 1H, $J = 13.4, 3.4$ Hz), 2.33 (s, 1H), 2.24 (t, 1H, $J = 2.8$ Hz), 2.17–0.94 (m, other aliphatic ring protons), 1.37, 1.13 (s, each 3H, 2 \times CH₃), 1.12 (s, 6H, 2 \times CH₃), 1.00, 0.81, 0.80 (s, each 3H, 3 \times CH₃), 0.69 (d, 1H, $J = 11.5$ Hz); ¹³C NMR (100 MHz, CDCl₃): δ 200.11, 175.46, 168.99, 128.54, 79.73, 78.76, 71.67, 61.81, 54.94, 48.02, 45.34, 43.51, 43.17, 41.79, 39.16, 39.12, 37.33, 37.07, 32.75, 31.89, 31.43, 29.30, 28.38, 28.09, 27.28, 26.45, 26.37, 23.33, 18.66, 17.46, 16.34

1.3 6^A-O-(*p*-Toluenesulfonyl)- β -CD (**14**)^[3]

β -CD (10.0g, 8.8 mmol) was suspended in 70 mL of water, and NaOH (1.06 g, 26.4 mmol) in 3.0 mL of water was added dropwise over 10 min. The suspension became homogeneous after the addition was complete. *p*-Toluenesulfonyl chloride (1.68 g, 8.8 mmol) in 4.0 mL CH₃CN was added dropwise over 20 min. A white precipitate was visible immediately after the start of the addition. The reaction mixture was stirred another 2 h at room temperature and then filtered. The filtrate was acidified to about pH 6-7 with 1N HCl and the product allowed to precipitate at 4°C overnight. The resulting white precipitate was recovered by suction filtration to provide 1.65 g of crude product. Recrystallization of hot water afforded **2** (1.07 g) as a white solid in 9.4% yield. $R_f = 0.52$ (*i*-PrOH:NH₄OH:H₂O = 5:2:2); ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.74 (d, 2H, $J = 7.6$ Hz, 2 \times arom-H), 7.42 (d, 2H, $J = 7.5$ Hz, 2 \times arom-H), 5.70 (br s, 14H, 14 \times OH), 4.83 (br s, 5H, 5 \times H₁), 4.75 (br s, 2H, 2 \times H₁), 4.30-4.33 (m, 2H), 4.16-4.19 (m, 2H), 3.20-3.64 (m, 44H, overlaps with HOD), 2.42 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 144.78, 132.70, 129.86, 127.55, 102.23, 101.97, 101.92, 101.28, 81.67, 81.57, 81.51, 81.44, 81.20, 80.80, 73.06, 72.93, 72.73, 72.69, 72.43, 72.37, 72.16, 72.04, 71.88, 69.68, 68.91, 59.93, 59.83, 59.81, 59.55, 59.30, 21.18; ESI-HRMS Calcd for C₄₉H₈₀NO₃₇S [M+NH₄]⁺: 1306.4124. Found 1306.4128.

1.4 6^A-Azido-6^A-deoxy-per-*O*-acetyl- β -CD (**16**)^[4, 5]

6^A-*O*-(*p*-tolsulfonyl)- β -CD (1.01 g, 0.78 mmol) was suspended in water (50 mL), NaN₃ (0.153 g, 0.24 mmol) was added. The reaction was carried out with stirring at 80°C for 12 h. The mixture was cooled to room temperature and poured into acetone (200 mL). The resulting precipitate was filtrated and dried in vacuo to give the azide product as a white power (0.736 g, 81%). $R_f = 0.37$ (*i*-PrOH:NH₄OH:H₂O = 5:2:2).

To a solution of 6^A-azido-6^A-deoxy- β -CD (160 mg, 0.14 mmol) in pyridine (2 mL) was added 16.8 mg of DMAP (0.14 mmol) and 1 mL Ac₂O at room temperature. The reaction mixture was stirred for 18 h under nitrogen. The solvent was removed in vacuo. The residue was subjected to flash chromatography (eluent: CH₂Cl₂:CH₃OH = 30:1) to give 237 mg (86%) of compound **4** as a white foam. $R_f = 0.57$ (CH₂Cl₂:CH₃OH = 10:1); ¹H NMR (400 MHz, CDCl₃): δ 5.13-5.27 (m, 7H, 7 \times H₃), 5.07 (d, 1H, $J = 3.9$ Hz, H₁), 5.00-5.04 (m, 5H, 5 \times H₁), 4.93 (d, 1H, $J = 3.8$ Hz, H₁), 4.68-4.77 (m, 7H, 7 \times H₂), 4.45-4.54 (m, 6H, 6 \times H₆), 3.98-4.25 (m, 13H, 6 \times H₆, 7 \times H₄), 3.60-3.73 (m,

9H, 2 × H₆, 7 × H₅), 1.95-2.08 (m, 60H, 20 × CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 170.57, 170.54, 170.51, 170.47, 170.43, 170.34, 170.32, 170.24, 170.21, 170.19, 170.07, 169.25, 169.21, 169.20, 169.17, 169.15, 96.81, 96.75, 96.59, 96.53, 96.40, 96.35, 77.21, 76.68, 76.54, 76.37, 76.28, 71.11, 70.89, 70.76, 70.63, 70.54, 70.37, 70.19, 70.13, 69.95, 69.72, 69.50, 69.38, 69.27, 69.25, 62.52, 62.44, 62.31, 50.53, 20.67, 20.59; ESI-HRMS Calcd for C₈₂H₁₁₃N₄O₅₄ [M+NH₄]⁺: 2017.6214. Found 2017.6179; C₈₂H₁₀₉N₃NaO₅₄ [M+Na]⁺: 2022.5768. Found 2022.5705; C₈₂H₁₁₀KN₃O₅₄ [M+H+K]⁺: 2039.5591. Found 2039.5624.

1.5 6^A-Azido-per-*O*-methyl-β-CD (**17**)^[4, 5]

To a solution of the azide product (365 mg, 0.31 mmol) in dried DMF (10 mL) was added 372 mg (60%, 9.3 mmol) of NaH at 0°C under nitrogen. After the reaction mixture was stirred at 0°C for 1 h, 0.72 mL of CH₃I (8.1 mmol) was added. The reaction mixture was stirred at 0°C for 1 h and then kept at room temperature for another 12 h under nitrogen. CH₃OH was added dropwise to quench the reaction and the solvent was removed in vacuo. The residue dissolved with CH₂Cl₂, washed with brine, dried with Na₂SO₄, filtrated and the solvent was removed in vacuo. The residue was subjected to flash chromatography (eluent: CH₂Cl₂:CH₃OH = 40:1) to give 280 mg (62%) of **3** as a white foam. R_f = 0.63 (CH₂Cl₂:CH₃OH = 10:1); ¹H NMR (400 MHz, CDCl₃): δ 5.08-5.13 (m, 6H, 6 × H₁), 5.05 (d, 1H, *J* = 3.7 Hz, H₁), 3.41-3.94 (m, 33H), 3.72 (m, 1H, H_{6β}^A), 3.64 (s, 3H, OCH₃), 3.63 (s, 3H, OCH₃), 3.62 (2 × s, 15H, 5 × OCH₃), 3.62 (m, 1H, H_{6α}^A), 3.50 (2 × s, 6H, 2 × OCH₃), 3.49 (s, 9H, 3 × OCH₃), 3.48 (s, 6H, 2 × OCH₃), 3.38 (s, 3H, OCH₃), 3.37 (s, 15H, 5 × OCH₃), 3.14-3.19 (m, 7H, 7 × H₂); ¹³C NMR (100 MHz, CDCl₃): δ 99.34, 99.12, 98.97, 98.86, 98.39, 82.10, 82.06, 82.00, 81.91, 81.87, 81.80, 81.74, 81.72, 81.43, 80.37, 80.27, 80.22, 80.18, 80.11, 80.01, 71.57, 71.45, 71.43, 71.37, 71.27, 71.13, 71.01, 70.96, 70.89, 70.84, 61.49, 61.45, 61.42, 61.39, 61.32, 61.30, 58.99, 58.96, 58.91, 58.64, 58.56, 58.52, 58.51, 58.45, 58.41, 52.07; ESI-HRMS Calcd for C₆₂H₁₁₃N₄O₃₄ [M+NH₄]⁺: 1457.7231. Found 1457.7279; C₆₂H₁₀₉N₃NaO₃₄ [M+Na]⁺: 1462.6785. Found 1462.6831; C₆₂H₁₀₉N₃O₃₄K [M+K]⁺: 1478.6519. Found 1478.6588.

1.6 3β-hydroxy-11-oxo-18β-olean-12-en-30-oic acid benzyl ester (**36**)^[6]


To a solution of glycyrrhetic acid **1** (1.05 g, 2.20 mmol) in DMF (20 mL) was added 367 mg of K_2CO_3 (2.6 mmol) and 320 μ L benzyl bromide (2.60 mmol). The resulting solution was stirred vigorously for 24 h at 60°C. The solvent was removed by steaming. The residue was purified by reverse column chromatography to give 1.10 g (89%) of compound **36** as a white solid. $R_f = 0.15$ (petroleum ether:ethyl acetate = 1:1); 1H NMR (400 MHz, $CDCl_3$): δ 7.39–7.32 (m, 5H), 5.54 (s, 1H), 5.20 (d, 1H, $J = 12.2$ Hz), 5.09 (d, 1H, $J = 12.2$ Hz), 3.22 (dd, 1H, $J = 10.6, 5.4$ Hz), 2.78 (td, 1H, $J = 13.5, 3.6$ Hz), 2.31 (s, 1H), 2.03–0.92 (m, other aliphatic ring protons), 1.34, 1.15, 1.13, 1.10, 1.00, 0.80, 0.73 (s, each 3H, $7 \times CH_3$), 0.68 (d, 1H, $J = 10.1$ Hz); ^{13}C NMR (100 MHz, $CDCl_3$): δ 200.14, 176.21, 169.01, 136.13, 128.62, 128.53, 128.30, 128.25, 78.75, 66.23, 61.79, 54.94, 48.21, 45.35, 43.99, 43.17, 41.08, 39.14, 37.65, 37.07, 32.77, 31.78, 31.17, 28.42, 28.30, 28.11, 27.31, 26.47, 26.41, 23.36, 18.68, 17.49, 16.38, 15.60

Reference:


- [1] S. Schwarz, S.D. Lucas, S. Sommerwerk, R. Csuk, Amino derivatives of glycyrrhetic acid as potential inhibitors of cholinesterases, *Bioorg Med Chem* 22 (2014) 3370-3378.
- [2] I. Beseda, L. Czollner, P.S. Shah, R. Khunt, R. Gaware, et al., Synthesis of glycyrrhetic acid derivatives for the treatment of metabolic diseases, *Bioorg Med Chem* 18 (2010) 433-454.
- [3] D. Vizitiu, C.S. Walkinshaw, B.I. Gorin, G.R.J. Thatcher, Synthesis of monofacially functionalized cyclodextrins bearing amino pendent groups, *J. Org. Chem.* 62 (1997) 8760–8766.
- [4] F. Giacalone, F. D'Anna, R. Giacalone, M. Gruttadauria, S. Riela, Cyclodextrin-[6]fullerene conjugates: synthesis, characterization, and electrochemical behavior, *Tetrahedron Lett.* 47 (2006) 8105–8108.
- [5] S. Xiao, Q. Wang, L. Si, X. Zhou, Y. Zhang, et al., Synthesis and biological evaluation of novel pentacyclic triterpene alpha-cyclodextrin conjugates as HCV entry inhibitors, *Eur J Med Chem* 124 (2016) 1-9.
- [6] R.K. Wolfram, L. Heller, R. Csuk, Targeting mitochondria: Esters of rhodamine B with triterpenoids are mitocanic triggers of apoptosis, *Eur J Med Chem* 152 (2018) 21-30.

2. Selected ^1H , ^{13}C NMR and HRMS spectra


^1H NMR of compound **9**




^{13}C NMR of compound **9**




¹³C NMR of compound **10**



HRMS of compound **10**




¹H NMR of compound 11




Liangl-115

¹³C NMR of compound 11




Liangl-115


HRMS of compound 11




¹H NMR of compound 12




¹³C NMR of compound **12**



HRMS of compound **12**




HSQC of compound 18




```
NAME      Liang2-125-hsqc
EXPNO     1
PROCNO    1
Date_     20190113
Time      11.19
INSTRUM   spect
PROBHD    5 mm PADUL 13C
PULPROG   hsqcetgp
TD         2048
SOLVENT   CDCl3
NS         6
DS         16
SWH        5341.880
FIDRES    2.608340
AQ         0.1917428
RG         2050
DW         93.600
DE         6.50
TE         196.6
```

H-H COSY of compound 18



```
NAME      Liang2-125-cosh
EXPNO     1
PROCNO    1
Date_     20190119
Time      20.36
INSTRUM   spect
PROBHD    5 mm PADUL 13C
PULPROG   cosygpmfqq
TD         2048
SOLVENT   CDCl3
NS         6
DS         16
SWH        5341.880
FIDRES    2.608340
AQ         0.1917428
RG         2050
DW         93.600
DE         6.50
TE         195.8
```



HRMS of compound 18



NL:
1.84E6
122_180824220059#5
15 RT: 5.01 AV: 1 T:
FTMS + p ESI Full ms
[200.00-3000.00]


NL:
3.04E5
C₁₁₅H₁₅₈N₄O₅₇ +H:
C₁₁₅H₁₅₉N₄O₅₇
pa Chrg 1

¹H NMR of compound 19




Liang2-64

¹³C NMR of compound **19**




HSQC of compound **19**



NAME	Liang2-64
EXPNO	4
PROCNO	1
Date_	20180413
Time	15.06
INSTRUM	spect
PROBHD	5 mm CPTCI 1H-
PULPROG	hsqcetgp
TD	2048
SOLVENT	CDCl3
NS	8
DS	16
SWH	5647.590
FIDRES	2.757612
AQ	0.1813663
RG	203
DW	88.533
DE	10.00
TE	300.4


HRMS of compound 19




NL:
1.64E7
123_180824173235#4
77 RT: 4.63 AV: 1 T:
FTMS + p ESI Full ms
[200.00-3000.00]

NL:
3.02E5
C₁₁₇H₁₆₂N₄O₅₈ +H:
C₁₁₇H₁₆₃N₄O₅₈
pa Chrg 1

¹H NMR of compound 20



HRMS of compound 20




NL:
2.09E6
124_180824173930#4
73 RT: 4.62 AV: 1 T:
FTMS + p ESI Full ms
[200.00-3000.00]

NL:
3.00E5
C 119 H 166 N 4 O 59 +H:
C 119 H 167 N 4 O 59
pa Chrg 1


¹H NMR of compound 21




Liang1-136



¹³C NMR of compound 21




HSQC of compound 21



NAME	Liang1-136
EXPNO	4
PROCNO	1
Date_	20171117
Time	11.59
INSTRUM	spect
PROBHD	5 mm CPTCI 1H-
PULPROG	hsqcetgpsi
TD	2048
SOLVENT	CDC13
NS	4
DS	16
SWH	5980.861
FIDRES	2.920342
AQ	0.1712628
RG	203
DW	83.600
DE	10.00
TE	300.4


HRMS of compound 21




NL:
4.39E7
125_180824174624#4
69 RT: 4.58 AV: 1 T:
FTMS + p ESI Full ms
[200.00-3000.00]

NL:
2.95E5
C₁₂₃H₁₇₄N₄O₆₁ +H:
C₁₂₃H₁₇₅N₄O₆₁
pa Chrg 1


¹H NMR of compound 22




HRMS of compound 22




¹H NMR of compound 23




¹³C NMR of compound 23




HSQC of compound 23




HRMS of compound 23




¹H NMR of compound 24




¹³C NMR of compound 24




HSQC of compound 24




HRMS of compound 24



¹H NMR of compound 25



HRMS of compound 25




NL:
6.37E7
129_180824181732#
285 RT: 2.75 AV: 1
T: FTMS + p ESI Full
ms [200.00-3000.00]

NL:
3.78E5
C₇₉ H₁₂₆ N₄ O₃₉ +H:
C₇₉ H₁₂₇ N₄ O₃₉
pa Chrg 1


¹H NMR of compound 26




Liang2-18




HRMS of compound 26



¹H NMR of compound 27




¹³C NMR of compound 27




Liang2-91


HSQC of compound 27




HRMS of compound 27




¹H NMR of compound 28



¹³C NMR of compound 28




HRMS of compound 28



¹H NMR of compound 29




Liang2-33




¹³C NMR of compound 29



Liang2-33




HRMS of compound 29



NL:
4.21E8
146_180824210130
#617 RT: 6.00 AV:
1 T: FTMS + p ESI
Full ms
[100.00-1500.00]


NL:
6.41E5
C₃₉H₆₁N₃O₃ +H:
C₃₉H₆₂N₃O₃
pa Chrg 1

¹H NMR of compound 30




Liang2-35


¹³C NMR of compound 30




HSQC of compound 30




HRMS of compound 30




¹H NMR of compound 31




¹³C NMR of compound 31




HSQC of compound 31




HRMS of compound 31




¹H NMR of compound 32




¹³C NMR of compound 32



HRMS of compound 32




HSQC of compound 33




HRMS of compound 33


132_180824183815 #513 RT: 5.03 AV: 1 NL: 3.38E6
T: FTMS + p ESI Full ms [200.00-3000.00]




¹H NMR of compound 34



¹³C NMR of compound 34




HSQC of compound 34



NAME Liang2-128-hsqc
EXPNO 4
PROCNO 1
Date_ 20180122
Time 9.48
INSTRUM spect
PROBHD 5 mm CPIC1 1H-
PULPROG hsqcetgpsisp2.2
TD 2048
SOLVENT DMSO
NS 8
DS 32
SWH 6793.478
FIDRES 3.317128
AQ 0.1507828
RG 203
DW 73.600
DE 10.00
TE 300.4


HRMS of compound 34




NL:
2.17E7
133_180824184508#
337 RT: 3.27 AV: 1
T: FTMS + p ESI Full
ms [200.00-3000.00]

NL:
3.76E5
C₈₀H₁₂₀N₄O₃₇+H:
C₈₀H₁₂₁N₄O₃₇
pa Chrg 1

¹H NMR of compound 35




HSQC of compound 35



```

NAME          Liang2-5
EXPNO         4
PROCNO        1
Date_         2017-212
Time          23.57
INSTRUM       spect
PROBHD        5 mm CPIC1 1H-
PULPROG       hsqcetpsi
TD            2048
SOLVENT       CDCl3
NS            16
DS            16
SWH           5081.301
FIDRES        2.481104
AQ            0.2015732
RG            203
DW            98.400
DE            10.00
TE            300.4
    
```

HRMS of compound 35




```

NL:
6.75E7
139_180824192638#
505 RT: 4.92 AV: 1
T: FTMS + p ESI Full
ms [200.00-3000.00]
    
```


```

NL:
3.27E5
C95H158N4O37 +H:
C95H159N4O37
pa Chrg 1
    
```



HRMS of compound 37




¹H NMR of compound 38




¹³C NMR of compound 38



HSQC of compound 38




HRMS of compound 38




NL:
1.43E6
136_180824190552#6
11 RT: 5.95 AV: 1 T:
FTMS + p ESI Full ms
[200.00-3000.00]

NL:
2.99E5
C₁₂₂H₁₆₃N₃O₅₈ +H:
C₁₂₂H₁₆₄N₃O₅₈
pa Chrg 1


¹H NMR of compound 39




¹³C NMR of compound 39



HSQC of compound 39




HRMS of compound 39




NL:
1.08E7
137_180824191247#4
95 RT: 4.79 AV: 1 T:
FTMS + p ESI Full ms
[200.00-3000.00]

NL:
3.04E5
C₁₁₅H₁₅₇N₃O₅₈ +H:
C₁₁₅H₁₅₈N₃O₅₈
pa Chrg 1


¹H NMR of compound 40




¹³C NMR of compound 40



HSQC of compound 40



HRMS of compound **40**



NL:
5.69E7
138_180824191943#
331 RT: 3.22 AV: 1
T: FTMS + p ESI Full
ms [200.00-3000.00]

NL:
3.97E5
C₇₅ H₁₁₇ N₃ O₃₈ +H:
C₇₅ H₁₁₈ N₃ O₃₈
pa Chrg 1